Fulcrum Therapeutics, Inc. Income Statement
FULC / Health Care|8 years of annual SEC 10-K data (FY2018-FY2025)
Line items include revenue, cost of goods sold, gross profit, operating expenses, interest, taxes, and net income with per-share data across 8 fiscal years. All figures from audited SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 8.44 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| SG&A Expense | $28.7M | $36.4M | $41.7M | $41.7M | $30.5M | $21.4M | $13.1M | $8.3M |
| R&D Expense | $56.1M | $63.4M | $71.8M | $76.8M | $69.7M | $59.0M | $71.1M | $25.2M |
| Operating Income | -$84.8M | -$21.9M | -$110.7M | -$112.6M | -$81.1M | -$71.6M | -$84.2M | -$33.5M |
| Income Tax | $0 | $0 | - | - | - | - | - | - |
| Net Income | -$74.9M | -$9.7M | -$97.3M | -$109.9M | -$80.8M | -$70.8M | -$82.7M | -$32.6M |
| EPS (Basic) | -$1.18 | -$0.16 | -$1.59 | -$2.44 | -$2.29 | - | - | - |
| EPS (Diluted) | -$1.18 | -$0.16 | -$1.59 | -$2.44 | -$2.29 | - | - | - |
| Shares Outstanding | 63.4K | 62.0K | 61.3K | 45.0K | 35.4K | 25.4K | 11.0K | 1.3K |